Who is sponsoring NCT02757677?

NCT02757677 is sponsored by Swiss Vision Network.

What drugs are being tested in NCT02757677?

Interventions in NCT02757677: Optical Coherence Tomography based Angiography.

Is NCT02757677 still recruiting?

NCT02757677 is currently terminated. Last updated 10 May 2022.

Last reviewed 2022-05-10 · How we verify

NCT02757677

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Blood Flow Characteristics in Glaucoma Using Optical Coherence Tomography Angiography (OCT-A).

Terminated Last updated 10 May 2022

What this trial tests

trial testing Optical Coherence Tomography based Angiography in Glaucoma in 200 participants. Terminated before completion.

Timeline

31 December 2015

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Swiss Vision Network
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	200
Start date	31 December 2015
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across Switzerland

Drugs / interventions tested

Optical Coherence Tomography based Angiography

Conditions studied

Glaucoma — all drugs for Glaucoma →

Sponsor

Swiss Vision Network

Who can join

18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to evaluate the efficacy of the new Optical Coherence Tomography based Angiography (OCT-A) softwares in the diagnosis and management of glaucoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of surgical intraocular pressure lowering on retinal structures - nerve fibre layer, foveal avascular zone, peripapillary and macular vessel density: 1 year results.
Ch'ng TW, Gillmann K, Hoskens K, Rao HL, et al · · 2020 · cited 34× · PMID 31409906 · DOI 10.1038/s41433-019-0560-6
Diurnal Variations of Peripapillary and Macular Vessel Density in Glaucomatous Eyes Using Optical Coherence Tomography Angiography.
Mansouri K, Rao HL, Hoskens K, D'Alessandro E, et al · · 2018 · cited 29× · PMID 29462016 · DOI 10.1097/ijg.0000000000000914

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other Swiss Vision Network trials

Trials by the same sponsor.

NCT03151577 — Longitudinal Study on Glaucoma Surgery Using XEN® Gel Stent · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02757677 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Vision Network
Last refreshed: 10 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02757677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing